ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
11.12
+0.71 (6.82%)
At close: Sep 26, 2025, 4:00 PM EDT
11.11
-0.01 (-0.09%)
After-hours: Sep 26, 2025, 7:40 PM EDT
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 115 employees as of December 31, 2024. The number of employees increased by 15 or 15.00% compared to the previous year.
Employees
115
Change (1Y)
15
Growth (1Y)
15.00%
Revenue / Employee
n/a
Profits / Employee
-$1,193,470
Market Cap
1.08B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Dec 31, 2021 | 78 | 17 | 27.87% |
| Dec 31, 2020 | 61 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ORIC News
- 22 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 24 days ago - ORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 4 weeks ago - ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer - GlobeNewsWire
- 6 weeks ago - ORIC® Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates - GlobeNewsWire
- 4 months ago - ORIC Pharmaceuticals Touts Positive Efficacy, Safety Data From Early-Stage Prostate Cancer Candidate, Raises Capital - Benzinga
- 4 months ago - ORIC® Pharmaceuticals Announces $125 Million Private Placement Financing - GlobeNewsWire
- 4 months ago - ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC - GlobeNewsWire